Open access
Oct 2026
The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme
Treatment with empagliflozin significantly decreased levels of circulating PRO-C3, reflecting attenuated systemic fibroblast activation, and to what extent this indicated antifibrotic effect may underpin the clinical effects of empagliflozin remains to be elucidated.
J. Jensen, C. Andersen, M. Omar et al.
· European Heart Journal · 0 citations